Arcutis Biotherapeutics, Inc. (ARQT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Arcutis Biotherapeutics, Inc. (ARQT)
Company Performance

Current Price

as of Oct 16, 2024

$9.72

P/E Ratio

N/A

Market Cap

$1.14B

Description

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Metrics

Overview

  • HQWestlake Village, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerARQT
  • Price$9.72+3.96%

Trading Information

  • Market Cap$1.14B
  • Float87.00%
  • Average Daily Volume (1m)1,841,093
  • Average Daily Volume (3m)2,003,961
  • EPS-$2.18

Company

  • Revenue$132.06M
  • Rev Growth (1yr)494.57%
  • Net Income-$52.33M
  • Gross Margin88.77%
  • EBITDA Margin-161.14%
  • EBITDA-$49.73M
  • EV$992.88M
  • EV/Revenue7.52
  • P/EN/A
  • P/S9.09
  • P/B6.07
Documents
SEC Filings
8-K (2024-08-14)
8-K (2024-06-18)
8-K (2024-05-14)
8-K (2024-04-10)
8-K (2024-03-04)
8-K (2024-02-28)
8-K (2024-02-27)
8-K (2024-02-15)
8-K (2024-01-11)
8-K (2023-12-18)
8-K (2023-11-03)
8-K (2023-10-23)
8-K (2023-10-19)
8-K (2023-09-27)
8-K (2023-08-18)
8-K (2023-08-14)
8-K (2023-08-08)
8-K (2023-06-05)
8-K (2023-05-24)
8-K (2023-05-09)
8-K (2023-02-28)
10-Q (2024-08-14)
10-Q (2024-05-14)
10-Q (2023-11-03)
10-Q (2023-08-08)
10-Q (2023-05-09)
10-K (2024-02-27)
10-K (2023-02-28)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Arcutis Biotherapeutics Q3 ($ 2.44, +0.22) (2023-11-03T16:16:53Z)
FDA Accepts Arcutis' sNDA for roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children down to age 6 ($2.04, 0.00) (2023-11-29T13:07:49Z)
Arcutis Biotherapeutics reports Q3 EPS ($0.73) vs FactSet ($0.91) [8 est, ($1.30)-(0.67)] ($2.22, 0.00) (2023-11-03T11:32:42Z)
Arcutis Biotherapeutics presents new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% ($3.88, 0.00) (2023-10-13T12:03:55Z)
Arcutis Biotherapeutics downgraded to neutral from buy at Mizuho Securities USA ($2.38, 0.00) (2023-10-26T08:07:45Z)
Arcutis Biotherapeutics downgraded to neutral from buy at Goldman Sachs ($3.88, 0.00) (2023-10-13T10:27:50Z)
Arcutis Biotherapeutics downgraded to hold from buy at Jones Research ($2.35, 0.00) (2023-11-08T00:48:12Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-03)
Earnings Report (2023-08-08)